Imperial College London - Revision history

Claire Robinson at 17:48, 28 November 2012

2012-11-28T17:48:18Z

Claire Robinson: /* Affiliations */

2012-11-28T14:30:37Z

Affiliations

Claire Robinson: /* Affiliations */

2012-11-28T14:28:30Z

Affiliations

Claire Robinson: /* Affiliations */

2012-11-28T14:24:01Z

Affiliations

Claire Robinson: /* Affiliations */

2012-11-28T14:23:44Z

Affiliations

Claire Robinson: /* Affiliations */

2012-11-28T14:22:57Z

Affiliations

Claire Robinson at 14:14, 28 November 2012

2012-11-28T14:14:18Z

Claire Robinson at 14:06, 28 November 2012

2012-11-28T14:06:04Z

Claire Robinson at 14:05, 28 November 2012

2012-11-28T14:05:37Z

Claire Robinson at 18:21, 27 November 2012

2012-11-27T18:21:56Z

@@ Line 3: / Line 3: @@
 The contact at the foot of the release was [[Tom Miller]], Imperial's director of communications.<ref>Imperial College London (2000), [http://www.imperial.ac.uk/college.asp?P=1518 Imperial College creates new Genetics and Genomics Research Institute], press release 31 Mar 2000, acc 27 Nov 2012</ref> Miller is a trustee and director of the [[Science Media Centre]].<ref>Charity Commission (2012), [http://www.charity-commission.gov.uk/Accounts/Ends27/0001140827_ac_20120331_e_c.pdf Science Media Centre Trustees' Report and Accounts for period ended 31 March 2012], acc 3 Oct 2012</ref><ref>Companies House (2012) [http://www.powerbase.info/images/f/f1/SMC-appointments.pdf Current Appointments Report for: Science Media Centre, created 23/11/2012], obtained from Companies House 23 Nov 2012</ref>
-In 2005 Imperial announced a research alliance with the [[Medical Research Council]] (MRC) and biotech company [[Affymetrix]]. Imperial's press release said, "The agreement will expand use of Affymetrixs microarray technology by Imperial and the MRC to target conditions such as cardiovascular disease, diabetes and cancer by analysing the genetic variations associated with them. Researchers hope this detailed understanding of how disease is caused at a molecular level will speed up translation from the laboratory to clinical trials, ultimately leading to new therapies."<ref>Imperial College London (2005 [http://www.imperial.ac.uk/college.asp?P=7142 New research alliance aims to speed up therapy development], 13 Dec, acc 28 Nov 2012</ref>
+In 2005 Imperial announced a research alliance with the [[Medical Research Council]] (MRC) and biotech company [[Affymetrix]]. Imperial's press release said, "The agreement will expand use of Affymetrix's microarray technology by Imperial and the MRC to target conditions such as cardiovascular disease, diabetes and cancer by analysing the genetic variations associated with them. Researchers hope this detailed understanding of how disease is caused at a molecular level will speed up translation from the laboratory to clinical trials, ultimately leading to new therapies."<ref>Imperial College London (2005 [http://www.imperial.ac.uk/college.asp?P=7142 New research alliance aims to speed up therapy development], 13 Dec, acc 28 Nov 2012</ref>
 ==Affiliations==

@@ Line 9: / Line 9: @@
 Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>
-Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[Ineos]]; energy companies [[Shell]], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
+Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[Ineos]]; energy companies [[Shell]], [[EDF]], and [[BP]]; and mining company [[Rio Tinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
 ==Funding==

@@ Line 9: / Line 9: @@
 Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>
-Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[INEOS]]; energy companies [[Shell]], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
+Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[Ineos]]; energy companies [[Shell]], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
 ==Funding==

@@ Line 9: / Line 9: @@
 Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>
-Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[INEOS]]; energy companies [[Shell], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
+Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[INEOS]]; energy companies [[Shell]], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
 ==Funding==

@@ Line 9: / Line 9: @@
 Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>
-Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; energy companies [[Shell], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
+Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; chemical company [[INEOS]]; energy companies [[Shell], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>
 ==Funding==

← Older revision		Revision as of 14:22, 28 November 2012
Line 8:		Line 8:

	Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>		Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>
		+
		+	Other corporate partners of Imperial include biotech company [[Syngenta]]; pharmaceutical companies [[Roche]], [[Merck]], [[Sanofi-Aventis]], [[Novartis]] and [[Pfizer]]; energy companies [[Shell], [[EDF]], and [[BP]]; and mining company [[RioTinto]].<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/majorresearchpartners Corporate partnerships], acc 28 Nov 2012</ref>

	==Funding==		==Funding==

← Older revision		Revision as of 14:14, 28 November 2012
Line 6:		Line 6:

	==Affiliations==		==Affiliations==
		+
		+	Imperial College has formed a partnership with biotech/medical firm [[AstraZeneca]] to determine the roles of certain proteins in breast cancer and drug resistance. The partnership is part of the [[Collaborative Awards in Science and Engineering]] (CASE) studentship scheme. The scheme, operated by the UK research councils, awards PhD studentships to partnerships between UK-based companies and academia in order to support collaborative postgraduate research. Imperial's partnership was established by Professor [[Eric Lam]], from the Department of Oncology at Imperial College.<ref>Imperial College London (2012) [http://www3.imperial.ac.uk/corporatepartnerships/partners/successes/studentship Imperial College partnership with AstraZeneca to determine the roles of FOXO proteins in breast cancer and drug resistance], undated, acc 28 Nov 2012</ref>

	==Funding==		==Funding==

← Older revision		Revision as of 14:05, 28 November 2012
Line 2:		Line 2:

	The contact at the foot of the release was [[Tom Miller]], Imperial's director of communications.<ref>Imperial College London (2000), [http://www.imperial.ac.uk/college.asp?P=1518 Imperial College creates new Genetics and Genomics Research Institute], press release 31 Mar 2000, acc 27 Nov 2012</ref> Miller is a trustee and director of the [[Science Media Centre]].<ref>Charity Commission (2012), [http://www.charity-commission.gov.uk/Accounts/Ends27/0001140827_ac_20120331_e_c.pdf Science Media Centre Trustees' Report and Accounts for period ended 31 March 2012], acc 3 Oct 2012</ref><ref>Companies House (2012) [http://www.powerbase.info/images/f/f1/SMC-appointments.pdf Current Appointments Report for: Science Media Centre, created 23/11/2012], obtained from Companies House 23 Nov 2012</ref>		The contact at the foot of the release was [[Tom Miller]], Imperial's director of communications.<ref>Imperial College London (2000), [http://www.imperial.ac.uk/college.asp?P=1518 Imperial College creates new Genetics and Genomics Research Institute], press release 31 Mar 2000, acc 27 Nov 2012</ref> Miller is a trustee and director of the [[Science Media Centre]].<ref>Charity Commission (2012), [http://www.charity-commission.gov.uk/Accounts/Ends27/0001140827_ac_20120331_e_c.pdf Science Media Centre Trustees' Report and Accounts for period ended 31 March 2012], acc 3 Oct 2012</ref><ref>Companies House (2012) [http://www.powerbase.info/images/f/f1/SMC-appointments.pdf Current Appointments Report for: Science Media Centre, created 23/11/2012], obtained from Companies House 23 Nov 2012</ref>
		+
		+	In 2005 Imperial announced a research alliance with the Medical Research Council (MRC) and biotech company [[Affymetrix]]. Imperial's press release said, "The agreement will expand use of Affymetrixs microarray technology by Imperial and the MRC to target conditions such as cardiovascular disease, diabetes and cancer by analysing the genetic variations associated with them. Researchers hope this detailed understanding of how disease is caused at a molecular level will speed up translation from the laboratory to clinical trials, ultimately leading to new therapies."<ref>Imperial College London (2005 [http://www.imperial.ac.uk/college.asp?P=7142 New research alliance aims to speed up therapy development], 13 Dec, acc 28 Nov 2012</ref>

	==Affiliations==		==Affiliations==

← Older revision		Revision as of 18:21, 27 November 2012
Line 29:		Line 29:
	<references/>		<references/>

−	[[Category:GM]]	+	[[Category:GM]][[Category:Human Genetics]]